News

President and CEO Michael Friedman, vice president Howard Udell, and chief scientific officer Paul Goldenheim, will each make a payment and plead guilty to a single “strict liability”

Bristol-Myers Squibb will pay Isis a $15 million upfront licensing fee, and will provide Isis with at least $9 million in research funding over a period of three

The trials are now under way in collaboration with the Johns Hopkins Sidney Kimmel Cancer Center in patients with chronic myelogenous leukemia (CML). The studies include a new

The FDA has asked for additional clinical data in support of the efficacy claim for the drug made by Seattle-based Dendreon, which is seeking a clarification as to

The studies showed that women who took Pristiq experienced a reduction in both the number and severity of hot flashes. Additional analyses demonstrated that Pristiq reduced the number

The US and the whistleblowers, former Medicis sales representatives, alleged that Medicis urged doctors to use Loprox as a treatment for diaper rash. The use of Loprox, which

Lupin has already received FDA approvals for the capsule form and the lower strength suspension, and with this approval the company can launch the entire product range, Mumbai-based

However, Teva is currently in patent litigation with Eli Lilly over the drug in the US District Court for the Southern District of Indiana. A suit was brought

The compound, GMX1777, was licensed worldwide from LEO Pharma. The open-label, dose-escalation trial will enroll approximately 18-24 patients with refractory solid tumors and lymphomas at a single center.